Illumina

The AI engine Fit Assessment

Beta

Illumina specializes in advanced technologies for analyzing genetic material, focusing on DNA, RNA, and protein analysis to support disease research and drug development. Their solutions aim to facilitate personalized medicine through innovative and scalable approaches.

Blurb

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.

HQ Location

United States

Founded

1998

Employees

5001 - 10000

Total funding raised

$1.28B

Last Funding Event

Post-IPO Debt, $500.00M, September 6, 2024

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Biomarker Identification
  • Genomic Data Analysis

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.